(Q46707269)

24 December 2017

title

siRNA targeting against EGFR, a promising candidate for a novel therapeutic application to lung adenocarcinoma (English)

1 reference

24 December 2017

1 reference

Sumitaka Yamanaka

1

1 reference

24 December 2017

Zhaodi Gu

2

1 reference

24 December 2017

Masami Sato

3

1 reference

24 December 2017

Rumi Fujisaki

4

1 reference

24 December 2017

Kenichi Inomata

5

1 reference

24 December 2017

Akira Sakurada

6

1 reference

24 December 2017

Akira Inoue

7

1 reference

24 December 2017

Toshihiro Nukiwa

8

1 reference

24 December 2017

Takashi Kondo

9

1 reference

24 December 2017

Akira Horii

10

1 reference

24 December 2017

publication date

11 March 2008

1 reference

24 December 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

published in

Pathobiology

1 reference

24 December 2017

volume

75

1 reference

24 December 2017

page(s)

2-8

1 reference

24 December 2017

issue

1

1 reference

24 December 2017

Estimates of the worldwide incidence of 25 major cancers in 1990.

cites work

1 reference

United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets

21 January 2018

1 reference

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

Lung cancer: intragenic ERBB2 kinase mutations in tumours

21 January 2018

1 reference

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment

21 January 2018

1 reference

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study

21 January 2018

1 reference

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 January 2018

1 reference

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

21 January 2018

1 reference

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000113789

1 reference

24 December 2017

PubMed ID

18334834

1 reference

24 December 2017